The substances under review -- including BPC-157, TB-500 and Semax -- are among those Joe Biden's administration restricted from compounding, notably over lack of human clinical trial data.
Glowing skin, deeper sleep, stronger muscles, an alert mind?
Such are the enticing promises of peptides, an increasingly buzzy class of substances touted by influencers and celebrities as the key to an optimized life.
Starting Thursday, a US review panel convened by the Food and Drug Administration is to consider whether seven of these peptides should be recommended for compounding -- when pharmacists or outsourcing facilities create custom drugs -- as interest in them surges.
Many medical experts have warned against that recommendation, citing a lack of evidence.
